Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268938 | 0.93 | FDPS (0.53) | FDPSLAP3SMPD1LPAR3LPAR2 | |
| SCHEMBL27811200 | 0.93 | FDPS (0.53) | FDPSLAP3SMPD1LPAR3LPAR2 | |
| SCHEMBL17053099 | 0.93 | FDPS (0.53) | FDPSLAP3SMPD1LPAR3LPAR2 | |
| SCHEMBL27811198 | 0.93 | FDPS (0.53) | FDPSLAP3SMPD1LPAR3LPAR2 | |
| SCHEMBL16938094 | 0.89 | FDPS (0.45) | FDPSPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3672437 | 0.88 | POLB (0.56) | FDPSPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9486473 | 0.84 | FDPS (0.47) | FDPSLAP3SMPD1LPAR3LPAR2 | |
| SCHEMBL27725191 | 0.83 | FDPS (0.48) | FDPSLAP3CA1CA2SMPD1 | |
| SCHEMBL3675752 | 0.81 | POLB (0.43) | FDPSPOLBCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9485820 | 0.80 | FDPS (0.52) | FDPSLAP3SMPD1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |